Výsledky vyhledávání - "Youssef Hijazi"

Akademický článek

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Autor: Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf, Matthias Klinger

Publikováno v: Experimental Hematology & Oncology, Vol 6, Iss 1, Pp 1-14 (2017)

Abstract Background Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laborat

Externí odkaz: https://doaj.org/article/c19fa123d37e404c918d9f88449602ec

Zobrazit plný text záznamu

Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges

Autor: Youssef Hijazi

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics. 46:163-172

The development of peptide therapeutics has increased enormously in recent decades. Many of the peptide drugs and antibody fragments that lack Fc backbone have a short half-life in circulation. In general, the half-life supports the design of the dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f551b7a46cf6ea29c1c0f3580b1555f4
https://doi.org/10.1007/s13318-020-00664-y

Zobrazit plný text záznamu

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes

Autor: Irina Velikyan, Veronique Tavernier, Olof Eriksson, Lars Johansson, Stefan Pierrou, Gunnar Antoni, Iina Laitinen, Michael Wagner, J. Tillner, Youssef Hijazi, Jan Erik Berglund, Lenore Teichert, Torsten Haack

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports

Unimolecular dual agonists for the glucagon-like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR) are emerging as a potential new class of important therapeutics in type 2 diabetes (T2D). Reliable and quantitative assessments of in vivo occupa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a538fad419d890a7cbfab3a436036ef
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-424041

Zobrazit plný text záznamu

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials

Autor: Lenore Teichert, Frank Wagner, Michael Wagner, Martin Bossart, Youssef Hijazi, Stefanie Keil, J. Tillner, Maximilian G. Posch, Torsten Haack, Philip J. Larsen, Christine Einig

Publikováno v: Diabetes, Obesity and Metabolism. 21:120-128

AIMS To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a novel polypeptide, active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCR), in healthy volunteers and in overweight/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763c740b34ddca1d112e47a5f89f6999
https://doi.org/10.1111/dom.13494

Zobrazit plný text záznamu

Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity

Autor: Y Xu, Min Zhu, Benjamin Wu, Youssef Hijazi, Y-N Sun, Andreas Wolf

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE®) antibody construct for treatment of leukemia. Transient elevation of cytokines (interleukin (IL)-6, IL-10, interferon-gamma (IFN-γ)) has been observed within the first 48 hours of continu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a560ef1ce88ba19bfa008113d5e9831
http://europepmc.org/articles/PMC4592530

Zobrazit plný text záznamu

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Autor: Andreas Viardot, Youssef Hijazi, Dieter Hoelzer, Svenja Neumann, Nicola Gökbuget, Dirk Nagorsen, Max S. Topp, Peter Kufer, Andreas Wolf, Evelyn Degenhard, Gerhard Zugmaier, Monika Brüggemann, Matthias Stelljes, Mariele Goebeler, Matthias Klinger, Christian Brandl, Ralf C. Bargou, Patrick A. Baeuerle

Publikováno v: Blood. 119:6226-6233

T cell–engaging CD19/CD3-bispecific BiTE Ab blinatumomab has shown an 80% complete molecular response rate and prolonged leukemia-free survival in patients with minimal residual B-lineage acute lymphoblastic leukemia (MRD+ B-ALL). Here, we report t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01a8b4be79d0a2f81f0667061d7cb47e
https://doi.org/10.1182/blood-2012-01-400515

Zobrazit plný text záznamu

Pharmacokinetics, Safety, and Tolerability of R411, a Dual α4β1-α4β7 Integrin Antagonist After Oral Administration at Single and Multiple Once-Daily Ascending Doses in Healthy Volunteers

Autor: Richat Abbas, Jian-Ping Tang, Horst A. Welker, Roger W. Blain, Louis M. Renzetti, Albert Dorr, Youssef Hijazi

Publikováno v: The Journal of Clinical Pharmacology. 44:1368-1378

R411 is a dual alpha4beta1-alpha4beta7 integrin antagonist under development for the treatment of chronic asthma. The objective of this study was to investigate the pharmacokinetics and safety of R411 and its active metabolite, RO0270608, in humans.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de171eb96a4d400f4b5c07d49082bd59
https://doi.org/10.1177/0091270004270147

Zobrazit plný text záznamu

Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury

Autor: Roselyne Boulieu, C. Bodonian, F. Salord, Youssef Hijazi, Magali Bolon

Publikováno v: British Journal of Anaesthesia. 90:155-160

Background. Ketamine is used as an anaesthetic agent for short surgical procedures, and as a sedative and analgesic in intensive care patients. Intensive care patients with brain or spinal cord injury may have physiological changes that could alter t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c7700871f466b3ff52c4abb984e1a6
https://doi.org/10.1093/bja/aeg028

Zobrazit plný text záznamu

Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms toN-Demethylation of Ketamine in Human Liver Microsomes

Autor: Youssef Hijazi, Roselyne Boulieu

Publikováno v: Drug Metabolism and Disposition. 30:853-858

Ketamine is a widely used drug for its anesthetic and analgesic properties; it is also considered as a drug of abuse, as many cases of ketamine illegal consumption were reported. Ketamine is N-demethylated by liver microsomal cytochrome P450 into nor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89368a74d4ef9f41975b245ca0cb402
https://doi.org/10.1124/dmd.30.7.853

Zobrazit plný text záznamu

Protein binding of ketamine and its active metabolites to human serum

Autor: Roselyne Boulieu, Youssef Hijazi

Publikováno v: European Journal of Clinical Pharmacology. 58:37-40

Ketamine is an anaesthetic agent extensively used in intensive care patients, and it has proved its efficacy in the management of burned patients. In these patients, alterations in serum protein binding occur that may have significant clinical implic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c5a3755124c651b56a597a5428f653
https://doi.org/10.1007/s00228-002-0439-4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání